pCLPG: A p53-driven retroviral system

Virology

Volumn 321, Issue 2, 2004, Pages 165-172

  Strauss, Bryan E ^a   Costanzi Strauss, Eugenia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chemotherapeutic drugs; LTR; p53; pCL; Retrovirus; Transcriptional regulation

Indexed keywords

PROTEIN P53; RETROVIRUS VECTOR;

ARTICLE; ENHANCER REGION; GENE EXPRESSION SYSTEM; GENE INSERTION; GENE TRANSFER; GENETIC TRANSDUCTION; GENOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; TRANSCRIPTION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS; WILD TYPE;

CELL LINE; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION, VIRAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; PROMOTER REGIONS (GENETICS); RETROVIRIDAE; TERMINAL REPEAT SEQUENCES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION;

UNIDENTIFIED RETROVIRUS;

EID: 1642446624     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2003.12.021     Document Type: Article

References (24)

1. Bajgelman M.C., Costanzi-Strauss E., Strauss B.E. Exploration of critical parameters for transient retrovirus production. J. Biotechnol. 103(2):2003;97-106.
2. Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12(2):1993;461-468.
3. Challita P.M., Skelton D., el-Khoueiry A., Yu X.J., Weinberg K., Kohn D.B. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J. Virol. 69(2):1995;748-755.
4. Chin K.V., Ueda K., Pastan I., Gottesman M.M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 255(5043):1992;459-462.
5. Chin K.V., Pastan I., Gottesman M.M. Function and regulation of the human multidrug resistance gene. Adv. Cancer Res. 60:1993;157-180.
6. DuBridge R.B., Tang P., Hsia H.C., Leong P.M., Miller J.H., Calos M.P. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7(1):1987;379-387.
7. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75(4):1993;817-825.
8. Funk W.D., Pak D.T., Karas R.H., Wright W.E., Shay J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12(6):1992;2866-2871.
9. Ghattas I.R., Sanes J.R., Majors J.E. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol. Cell. Biol. 11(12):1991;5848-5859.
10. Gorman C.M., Moffat L.F., Howard B.H. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2(9):1982;1044-1051.
11. Hanania E.G., Giles R.E., Kavanagh J., Fu S.Q., Ellerson D., Zu Z., Wang T., Su Y., Kudelka A., Rahman Z., Holmes F., Hortobagyi G., Claxton D., Bachier C., Thall P., Cheng S., Hester J., Ostrove J.M., Bird R.E., Chang A., Korbling M., Seong D., Cote R., Holzmayer T., Deisseroth A.B.et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc. Natl. Acad. Sci. U.S.A. 93(26):1996;15346- 15351.
12. Haupt Y., Maya R., Kazaz A., Oren M. mdm2 promotes the rapid degradation of p53. Nature. 387(6630):1997;296-299.
13. Hesdorffer C., Ayello J., Ward M., Kaubisch A., Vahdat L., Balmaceda C., Garrett T., Fetell M., Reiss R., Bank A., Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol. 16(1):1998;165-172.
14. Kern S.E., Kinzler K.W., Bruskin A., Jarosz D., Friedman P., Prives C., Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science. 252(5013):1991;1708-1711.
15. Kern S.E., Pietenpol J.A., Thiagalingam S., Seymour A., Kinzler K.W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 256(5058):1992;827-830.
16. Ko L.J., Prives C. p53: puzzle and paradigm. Genes Dev. 10(9):1996;1054-1072.
17. Michalovitz D., Halevy O., Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 62(4):1990;671-680.
18. Michieli P., Chedid M., Lin D., Pierce J.H., Mercer W.E., Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res. 54(13):1994;3391-3395.
19. Miyashita T., Harigai M., Hanada M., Reed J.C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54(12):1994;3131-3135.
20. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B., Reed J.C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9(6):1994;1799-1805.
21. Naviaux R.K., Costanzi E., Haas M., Verma I.M. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70(8):1996;5701-5705.
22. Seoane J., Le H.V., Massague J. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 419(6908):2002;729-734.
23. Strauss B.E., Shivakumar C., Deb S.P., Deb S., Haas M. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53. Biochem. Biophys. Res. Commun. 217(3):1995;825-831.
24. Subler M.A., Martin D.W., Deb S. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66(8):1992;4757-4762.